FDA extends review of Capricor cell therapy; Pain drug startup to go public

FDA extends review of Capricor cell therapy; Pain drug startup to go public →

The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the public markets.